Latin America Antibody Drug Conjugates Market Research Report - Segmented By pipeline, Technology, End User & Country (Mexico, Brazil, Argentina, Chile & Rest of Latin America) - Industry Size, Share, Trends, Growth, Forecast | 2024 to 2029

Updated On: January, 2024
ID: 5802
Pages: 145

The Market Size of Antibody Drug Conjugates in Latin America was worth USD 1.40 billion in 2022, to reach USD 4.04 billion by 2027 and is estimated to grow with a CAGR of 23.65% during the forecast period from 2022 to 2027.


In 2013 Mexico, cancer is the main cause for 12.84% of all death. It is predicted to reach 1,262,861 by the end of 2020. Escalating a huge number of investments made by the pharmaceutical and biotechnology industries for the research and development activities, a rising number of manufacturing companies and increasing occurrence of cancer cases are mounting the business growth. Escalating adoption of unhealthy urban lifestyles poises critical cancer cases, and improvements in technological advancements are mounting the market demand. Escalating research activities for antibody therapies, rising pre-clinical researches, and augmenting research on oncology diseases are expected to drive the market growth.


The treatment associated with the cancer is increasing, which in turn hindering the business growth. Shortage of expertise manufacturers and lack of funds towards research and development activities and regulatory trials may hamper the market growth. Strict rules and guidelines from the FDA and side-effects post-treatment may limit business growth.

Latin America Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories 

  • By pipeline: Phase, Mode of action( Igg1 antibodies, HER2 antibodies), Technology, linker.
  • By Technology: Seattle genetics, Immunogen, Immunomedics.
  • By End User: Research institutes, Hospitals, Clinics.
  • By Country: Mexico, Brazil, Argentina, Chile & the Rest of Latin America.

Regional Analysis

The market is driven by a considerable rise in elderly people, regular product approvals by the FDA, and the increasing popularity of antibody-drug conjugates due to exact targeting and better technologies. Factors like on-going developments in clinical data, advancements in technology, escalating patient count suffering from cancer, and boosting collaborations among the key players are contributing majorly to the market share.

ReceptaBio is a Brazilian company committed to the research and development of novel drugs for treating cancer patients. According to the data published in the journal of Cancer Epidemiology, the factors like lifestyle risks accounts to hold 114,497 cancer cases every year in Brazil, representing 27% of all types of cancers and 63,000 cancer deaths of 34% of the death rate caused by cancer.

The ADC market is driven by factors like growing theoretical research activities, and in Brazil, prostate cancer and female breast cancer affect an estimated 68,000 and 60,000 men and women, respectively. In Mexico, the demand for the antibody-drug conjugates market is surging for the past few years. Government organizations are planning to create awareness among people over the availability of different treatment procedures, which is fuelling the demand of the market.

Noteworthy Companies dominating the Latin America Antibody Drug Conjugates Market Profiled in the Report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample